MHLW Approves Novartis’ Five New Therapies Expanding its Footprints in Japan

MHLW Approves Novartis’ Five New Therapies Expanding its Footprints in Japan

Shots:

  • The five therapies include Tabrecta (capmatinib) for advanced and recurrent unresectable NSCLC, Entresto (sacubitril valsartan sodium hydrate) for chronic HF, Mayzent (siponimod fumaric acid) for secondary PMS, Enerzair (glycopyrronium bromide, indacaterol acetate, mometasone furoate) and Atectura (indacaterol acetate, mometasone furoate) for different forms of asthma
  • In 2020, Novartis has received seven approval in Japan which include Zolgensma for SMA and Beovu for wet AMD in addition to these five therapies
  • These approval boost Novartis’ pipeline and offers Japanese patients a broad range of novel treatment options targeting their medical needs

Click here to read full press release/ article | Ref: Novartis | Image: GMP News

Related News: Novartis’ Zolgensma (onasemnogene abeparvovec) Receives MHLW’s Approval for Spinal Muscular Atrophy